arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Nuo Therapeutics, Inc.

AURX
Price unavailable
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
54 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Nuo Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap
Dividend Yield
Revenue Growth 168.8%
Op. Margin -34.3%
ROIC 25.5%
FCF / Share $-0.02
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.30M
↑ +168.8%
Net Income Profit after all expenses
$-618.47K
↑ +17.1%
Operating Margin Operating profit as % of sales
-34.3%
↑ +34.5% 3th
FCF / Share Free cash flow per share
$-0.02
↓ -233.8%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
100
Financial Health
6
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters